-
Pediatric blood & cancer · Nov 2014
Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.
- Olga Moser, Manuela Krumbholz, Christian Thiede, Josephine T Tauer, Indra Janz, Melchior Lauten, Dagmar Dilloo, Markus Metzler, and Meinolf Suttorp.
- Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.
- Pediatr Blood Cancer. 2014 Nov 1; 61 (11): 2080-2.
AbstractApproximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.© 2014 Wiley Periodicals, Inc.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..